Results:
16,214 AF patients on liraglutide were propensity score matched to AF patients not on liraglutide. They were matched for demographics, cardiovascular procedures, cardiovascular medications, hypertension, diabetes, heart failure, ischemic heart disease, and diabetic medications. AF patients on liraglutide were found to have a significantly lower risk of all-cause mortality (HR 0.67, 95% CI 0.631 – 0.711, p < 0.001). There was a tendency toward lower risk of stroke, acute heart failure, and acute coronary syndrome but was not statistically significant.